Bedford Labs Recalls Drug - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Bedford Labs Recalls Drug

Pharmaceutical Technology

Bedford Labs Recalls Drug

Bedford Laboratories (Bedford, OH, www.bedfordlabs.com), a division of Ben Venue Laboratories, Inc., (Bedford, OH, www.benvenue.com) voluntarily recalled one lot of famotidine injection, 20 mg/2-mL (NDC 55390-029-10), lot no. 609336, with an expiration date of April 2006, because of a lack of sterility assurance.

The prescription product was distributed in August 2004 throughout the United States to wholesalers and distributors, who further distributed the product to hospitals. According to an FDA posting, customers that have any vials of this lot of famotidine injection should discontinue distribution and use of the drug immediately and contact Bedford Laboratories' customer service department (tel. 800.562.4797) for a returned goods authorization.

Bedford Laboratories is working with FDA on this recall, and to date no serious health or safety reports have been attributed to the defective lot.

ADVERTISEMENT

RELATED CONTENT
FDA's CMC Pilot Program Moves Forward
FDA Sets Guidance Agenda
A Compliance Perspective on Dissolution Method Validation for Immediate-Release Solid Oral Dosage Forms on Automated Instrumentation
21 CFR Part 11 Revision Delayed, But Moves Forward
Qualification, Validation, and Verification
blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
19%
To all process for new products only
14%
To select process for new products only
24%
To select processes for both new and legacy products
19%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here